33 C
Vientiane
Friday, May 23, 2025
spot_img
Home Blog Page 113

FutureLink Boston 2025 Reinforces TraceLink’s Leadership in Supply Chain Orchestration and Innovation

BOSTON, May 7, 2025 /PRNewswire/ — TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, successfully hosted FutureLink Boston 2025, bringing together more than 150 attendees ranging across senior executives, industry experts, and supply chain technology innovators from across the end-to-end healthcare and life sciences ecosystem. Now in its ninth year, FutureLink remains the only industry event focused exclusively on safeguarding and advancing the digital transformation of the end-to-end life sciences and healthcare supply chain.

With an agenda specifically designed to bridge the gap between strategic vision and operational execution, FutureLink Boston offered a unique opportunity for attendees to gain direct insight from the companies shaping the future of life sciences and healthcare. Over three days, attendees explored how digitalization, real-time supply and demand data, and generative AI are transforming supply chain operations and delivering meaningful impact to patients worldwide.

“With representation from every corner of the supply chain, FutureLink is unmatched in its ability to bring the healthcare and life sciences industry together to transform vision into action,” said Shabbir Dahod, President and CEO of TraceLink. “It’s the only forum where innovation at the intersection of supply chain digitalization, regulatory readiness, and agentic orchestration converge to drive measurable impact—all powered by an integrate-once digital business network that doesn’t exist anywhere else in the world. That network is the foundation for building intelligent, linked, and patient-centric supply chains, and FutureLink is one of the ways we bring that leadership to life.”

Driving Digital Transformation Across the Industry
With 26 industry speakers and nearly 50 total sessions, the event showcased how customers are using the TraceLink Orchestration Platform for Universal Solutions (OPUS) to orchestrate supply chain relationships, digitalize critical business processes, and supply generative AI models and enterprise systems with real-time supply chain data. A special focus was placed on:

  • Leveraging DSCSA and serialization investments as a foundation for digital transformation.
  • Ensuring DSCSA readiness among more than 5,000 companies and 650 TraceLink DSCSA customers already deploying more than 10,000 EPCIS links.
  • Using TraceLink Multienterprise Information Network Tower (MINT) to exchange more than 40 commercial transactions, including purchase orders, inventory balances, advanced ship notices, and invoices, to build intelligent orchestration layers on existing track-and-trace infrastructure.
  • The need for collaborative trading partner execution for critical processes such as DSCSA compliance exception management through solutions like TraceLink Process Orchestration for Empowered Teams (POET).
  • Fueling generative AI initiatives with foundational, real-time supply chain data to create agentic orchestration experiences.
  • Leveraging the open OPUS service, solution, and technology partner ecosystem for digital transformation acceleration, as evidenced by the presence of 19 different solution and technology partner companies at the conference.

FutureLink Boston set the stage for what’s next in global supply chain transformation. This fall, the momentum continues in Europe. Registration is now open for FutureLink Barcelona—join us October 6-8, 2025 to collaborate with industry leaders, explore breakthrough innovations, and accelerate your journey toward a more agile, intelligent, and patient-centric supply chain.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.

Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World

SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ — Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, located in Singapore’s vibrant biomedical hub. The new site dramatically shortens turnaround times for researchers from Seoul to Sydney, delivering the world’s fastest, highest‑accuracy, and most cost-effective sequencing services.

Sequencing at the Speed of Modern Science

Plasmidsaurus was founded to help scientists work faster. Despite incredible advancements in DNA sequencing technology that have dramatically accelerated the speed and lowered the cost of sequencing genomes, many biomedical researchers are still using sequencing technologies from the 1970s to advance their daily experiments. Plasmidsaurus believes that scientists shouldn’t have to put up with slow turnaround times and unreliable or inconclusive results that stall their progress.

Singapore has a thriving and growing research community, bolstered by a S$25B investment in Research, Innovation and Enterprise, including significant support for cell and gene therapy, healthcare, and epidemic preparedness. But researchers across the Asia-Pacific region are often stuck with sequencing options that take weeks and cost more than twice what scientists in the US and Europe can expect. The new lab reflects Plasmidsaurus’ mission to deliver the fastest and more reliable sequencing to accelerate R&D for biopharmaceutical companies, CDMOs, and advanced research institutions around the world.

Global reach, local impact

“Our tenth lab is more than a milestone—it’s a signal that great science shouldn’t be gated by geography,” said Mark Budde, cofounder and CEO of Plasmidsaurus. “Whether you’re debugging an AAV vector for a gene therapy in Boston or validating a plasmid for clinical manufacturing in Singapore, you’ll get the same data quality and overnight turnaround our customers all over the world rely on.”

Plasmidsaurus’s network of labs benefits from the company’s innovation in molecular biology, laboratory automation, bioinformatics software, and logistics that drive incredible speed and industry-leading accuracy across a wide range of sequencing services. For researchers and biotech and pharma companies scaling up research and development, that translates to faster design-build-test cycles, more reliable results, and less time spent troubleshooting logistics.

“We love sequencing with Plasmidsaurus to validate clones,” said Jonathan Bester, co-founder of Singapore-based biotech startup Peptobiotics. “It’s faster, less tedious, and more comprehensive than Sanger, translating to better and faster experiments and shorter R&D timelines overall. The new lab in Singapore is going to be a game-changer for us.”

Learn more

For researchers interested in learning more about Plasmidsaurus and the services available through the Singapore lab, you can register for an upcoming webinar with Plasmidsaurus Technical Support Specialist Andrew Willis on Thursday, May 7th at 10am SGT.

About Plasmidsaurus

Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity for scientists. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel Prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers and has been cited in more than 800 publications to date. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. For more, visit: https://plasmidsaurus.com/

Media Contact
press@plasmidsaurus.com

 

Lee Kum Kee Celebrates AAPI Culinary Culture with Launch of #FlavorsofAAPI Initiative – Bridging Generations Through Authentic Asian Flavor

LOS ANGELES, May 6, 2025 /PRNewswire/ — In celebration of AAPI Heritage Month, Lee Kum Kee, the global leader in authentic Asian sauces and condiments, proudly reinforces its commitment to honoring Asian heritage, culinary traditions, and community empowerment. Rooted in over 137 years of history, Lee Kum Kee has long been an integral part of the AAPI community’s kitchens—enabling generations of home cooks, chefs, and restaurateurs to create authentic flavors that reflect their cultural identity and personal journeys.

This year’s AAPI Heritage Month theme, “Self-Made Success & Resilience,” resonates deeply with Lee Kum Kee’s legacy. Founded in 1888 by Lee Kum Sheung, a self-made entrepreneur who accidentally invented oyster sauce, the brand has grown from a small family business to a globally recognized household name. Today, Lee Kum Kee empowers millions of families and restaurants worldwide to explore the richness of Asian cuisine, ensuring that the flavors of tradition remain alive while evolving with contemporary tastes.

Honoring AAPI Culinary Traditions & Community

Throughout history, food has been a powerful way for the AAPI community to preserve heritage and share culture with the world. From handmade dumplings passed down through generations to modern fusion dishes that reflect the Asian American experience, Lee Kum Kee has been an essential ingredient in countless family recipes—helping to bridge tradition with innovation.

“As a proud supporter of the AAPI community, we take great pride in our role in helping individuals express their cultural identity through food,” said Elaine Thai, Vice President of Marketing, Lee Kum Kee USA. “This month, we celebrate the resilience and creativity of the AAPI community by continuing to support their self-made success stories, whether in their home kitchens, restaurants, or culinary businesses.”

Supporting AAPI Communities

In honor of AAPI Heritage Month, Lee Kum Kee have been expanding efforts to uplift the community through shining a spotlight on the success stories of AAPI chefs who are shaping the next generation of Asian cuisine. From Chef Katianna Hong of Yangban, who goes beyond traditional fusion to celebrate the diverse experiences of the Korean American community, to Chef Winnie Yee of Smoke Queen Barbecue, who infuses bold Asian flavors into classic Texas-style barbecue, inspired by her Malaysian Chinese heritage. From Chef Barb Batiste of Big Boi, who honors her Filipino roots by sharing her mother’s cherished recipes, to Chef Tue Nguyen of ĐiĐi, who brings authentic Vietnamese flavors to life through bold, modern interpretations—rising to prominence as a TikTok sensation. Together, these AAPI chefs are redefining American cuisine through the lens of heritage and creativity. These stories spotlight the personal journeys, cultural heritage, and culinary creativity of AAPI chefs, giving voice to the people who bring Asian flavors to life across the country. By sharing these narratives, Lee Kum Kee honors tradition while inspiring future generations of AAPI culinary talent.      


Join the Celebration for AAPI Culinary Culture 

Lee Kum Kee invites everyone to celebrate AAPI Heritage Month by cooking, sharing, and honoring the flavors that define Asian American culture. Follow the conversation using #FlavorsofAAPI to share your stories and explore authentic Asian recipes at USA.LKK.com.

About Lee Kum Kee

Lee Kum Kee, established in 1888, is the global gateway to Asian culinary culture. Originating from a single restaurant in Nanshui, China, it has grown into a global brand, empowering restaurants and millions of home cooks to explore Asian flavors and culinary culture. Beloved by consumers and chefs alike, the family-owned brand offers over three hundred authentic sauces and condiments, including favorites like Sriracha Chili Sauce, Sriracha Mayo, Premium Soy Sauce, Hoisin Sauce, Oyster Flavored Sauce, Chili Crisp Oil and more With a rich heritage and commitment to quality, Lee Kum Kee has expanded its presence in more than 100 countries across five continents through international retailers, specialty stores, and online at USA.LKK.com. For more information, follow Lee Kum Kee on Instagram, YouTube, Facebook, TikTok and Pinterest

Coenda Clarifies Inaccuracies in Recent INEO Tech Corp. Disclosure

Surrey, British Columbia – Newsfile Corp. – 6 May 2025 – Coenda Investments Holding Corp. (“Coenda“), a significant shareholder of INEO Tech Corp. (TSXV: INEO) (OTCQB: INEOF) (“INEO“), issues this press release to correct several inaccuracies contained in the recent disclosure by INEO dated April 28, 2025.

Coenda firmly believes that rigorous corporate governance and regulatory compliance are foundational to long-term shareholder value creation.

During preliminary discussions about Coenda’s strategic investment in INEO, Coenda highlighted concerns to INEO’s management about its growth strategy, but after nearly a year of discussions, Coenda was convinced of the merits of INEO’s product and service offering. Coenda chose to make a significant investment in INEO based on the strength of INEO’s product and service offering, and with the mutual understanding that:

  1. There was a need to strengthen INEO’s board by bringing on new members who could play a proactive role in INEO’s global growth, oversight of management, and adherence to good governance practices;
  2. INEO’s management team would need to be strengthened by adding additional depth to grow in global markets; and,
  3. INEO would be fully transparent in the use of the proceeds of Coenda’s investment.

Over the past quarter, in countless meetings, Coenda has worked tirelessly to implement the changes that it identified to INEO’s management before Coenda made its investment. Coenda has also sought information from INEO about the use of the proceeds of Coenda’s investment. At all times, Coenda’s objective in making its strategic investment, and in taking an active role in facilitating the changes identified to INEO’s management, was to grow INEO and enhance shareholder value.

Despite Coenda’s patient efforts to implement the changes that were contemplated as part of Coenda’s strategic investment, Coenda has been met with resistance from INEO’s management team.

Following the appointment of Coenda’s nominee (Mr. Kerem Akbas) to the board of INEO, it became apparent that important corporate formalities, such as board approval of financial statements and timely filing of continuous disclosure, were not being followed. Consequently, Coenda delivered a requisition for a shareholder meeting, to be held on an urgent basis, to ascertain the root cause for INEO’s corporate and regulatory non-compliances. Coenda also gave notice of its desire to change the then-current board members except for Mr. Akbas (i.e. Greg Watkins, Kyle Hall, and Steve Matyas).

On the date that Coenda’s requisition was delivered, it had not, and as of the date of this press release, Coenda has not identified or proposed a slate of directors to replace Mssrs. Watkins, Hall, and Matyas. Coenda has not, and does not presently intend before the shareholder meeting scheduled for August 8, 2025, to acquire any additional securities in INEO. Similarly, Coenda has not, and does not presently intend to publicly solicit proxies with respect to the proposals it has advanced for the upcoming shareholder meeting.

Coenda reaffirms its position that the proposed board changes are solely intended to address governance and compliance issues and are not part of any broader strategy or intention to acquire further shares or influence corporate control.

Coenda notes the following corrections to INEO’s press release dated April 28, 2025:

  1. Assurances Regarding Board Changes: Coenda never provided assurances that it would not seek changes to the board. On the contrary, pursuant to an investor’s rights agreement approved by the shareholders of INEO, one condition of Coenda’s investment was altering INEO’s board composition to permit the appointment of Coenda’s nominee, Mr. Kerem Akbas. Any representations made to the TSX by INEO were made without Coenda’s consent.
  2. Strategic Investment: Coenda’s investment in INEO was intended to bolster INEO’s finances and to strategically strengthen its competitiveness. At all times, Coenda has been actively involved in the governance and affairs of INEO, and it was a condition of Coenda’s investment that it would be entitled to at least one board seat. Mr. Akbas, the primary shareholder of Coenda, has extensive global experience in INEO’s industry. Mr. Akbas has offered his wealth of knowledge to INEO to maximize long-term shareholder value, including by bringing a significant contract, making introductions to a credible producer, and facilitating a world-class sales channel partnership. Regrettably, Mr. Akbas’ queries, suggestions, and proposals have, to date, been met with significant resistance from INEO.
  3. Incomplete Disclosure of Coenda’s Requisition: The full text of Coenda’s requisition, which provides context and the basis for the resolutions proposed by Coenda, has not been disclosed to shareholders by INEO. Coenda expects that the full text of its requisition will be provided to all shareholders in the company’s information circular as required by Sections 167(5)(b) and 167(6)(b) of the British Columbia Business Corporations Act.
  4. Coenda’s Incorporation and History: Coenda was incorporated on January 11, 2022. Contrary to INEO’s characterization, Coenda is not a recently formed investment company.
  5. Disclosure Obligations on Director Resignation: INEO incorrectly characterized the resignation of Eugene Syho, a director and Chair of the Audit Committee, as non-material. Under TSX Venture Exchange policies 3.1 and 3.3, issuers must immediately disclose changes in directors. INEO first disclosed Mr. Syho’s resignation in an unrelated press release on February 11, 2025, “INEO Announces Deployment of Retail Media Technology with Leading Turkish Retailer Bambi, via Partner Bon Intelligence.” To date, no material change report regarding Mr. Syho’s resignation has been filed, despite Coenda’s repeated requests.
  6. Unanimous Consent Required Under BC Business Corporations Act and INEO’s Articles: Coenda clarifies that under the British Columbia Business Corporations Act and INEO’s articles, for a written resolution to be effective in lieu of a meeting, directors must unanimously consent. The resolution approving INEO’s interim financial reports and the related management discussion and analysis for the period ending December 31, 2024, and authorizing filing thereof, were not approved unanimously as required. Mr. Akbas, in his capacity as director of INEO, did not sign or assent to the proposed consent resolution because he was not provided with a copy of the audit committee’s resolution recommending approval referred to in the proposed director resolution until April 21, 2025. The filing of INEO’s interim financial statements and management discussion and analysis for the period ending December 31, 2024 were not properly authorized under INEO’s articles or applicable law.
  7. Correction of Ownership Percentage: INEO inaccurately reported Coenda’s shareholding at the time Coenda’s investment was completed as 49%. As of January 22, 2025, when the transaction closed, Coenda held 50.78% of the issued and outstanding shares of INEO. As required by applicable regulation, Coenda disclosed its acquisition of a controlling interest in INEO in the early warning report prepared and filed by McMillan LLP, the solicitors for INEO. Following the conversion of a debenture on February 21, 2025, Coenda’s shareholdings were diluted to 48.85% of INEO’s outstanding shares.

Coenda’s primary goal remains to enhance corporate governance and oversight, which is crucial for INEO’s sustainable growth and shareholder confidence. Coenda is committed to ensuring transparency and accountability at INEO and looks forward to addressing these issues fully at the upcoming requisitioned shareholders’ meeting.

The issuer is solely responsible for the content of this announcement.

About Coenda Investments Holding Corp.

Coenda Investments Holding Corp. is a private British Columbia company committed to enhancing shareholder value through strategic investments and by fostering governance transparency and accountability.

For more information, please contact:

Dawn Wattie, SVP Legal
778-846-5749
“Dawn Wattie”
COENDA INVESTMENT
HOLDINGS CORP.

HTX Premieres USD1 Stablecoin Globally, Partnering with World Liberty Financial to Forge a New Era of Decentralized Economy

SINGAPORE, May 6, 2025 /PRNewswire/ — HTX, a leading global cryptocurrency exchange, has officially announced the listing of the USD1 stablecoin, becoming the first platform worldwide to support trading of this asset. This milestone underscores HTX’s ongoing commitment to supporting high-quality blockchain projects and advancing the cryptocurrency ecosystem. USD1, a compliant stablecoin issued by World Liberty Financial (WLFI), is pegged 1:1 to the US dollar. The stablecoin is custodied by BitGo Trust Company, ensuring full compliance with US financial regulatory standards and providing users with a reliable digital asset solution.

USD1’s Vision: Disrupting Legacy Financial Systems

During TOKEN 2049, Justin Sun, Advisor to HTX and Founder of TRON engaged in a discussion with Eric Trump, son of the US President, and WLFI Co-founder Zach Witkoff. Zach directly addressed three fundamental challenges within the traditional financial system:

  • Lack of Transparency in Traditional Finance
  • Financial Exclusion of a Significant Global Population
  • Inefficient Cross-Border Payment Processes

The introduction of USD1 directly addresses these issues, aiming to redefine the concept of stablecoin. The goal for USD1 is to become the most compliant, transparent, and trustworthy stablecoin globally, evidenced by monthly audit reports and complete openness regarding its underlying asset reserves for institutional scrutiny. Eric Trump lauded the proactive role of compliant and transparent stablecoins like USD1 in promoting the internationalization of the US dollar and expressed optimism about the transformative potential of blockchain technology in reshaping traditional finance.

Justin emphasized that financial freedom is a core tenet of blockchain technology. The launch of USD1 and the collaboration with WLFI represent a significant step towards the convergence of DeFi and TraFi, with the aim of enabling every user to effortlessly utilize stablecoins via their mobile devices and participate in the global financial system.

As of May 6, USD1 has achieved a total market capitalization of approximately $2.12 billion, ranking prominently at 45th on CoinMarketCap, demonstrating rapid growth.

HTX Empowers Premium Projects, Fostering Long-Term Crypto Ecosystem Growth

As a leading global cryptocurrency exchange, HTX is committed to its listing strategy of “supporting quality projects and creating value for users.” Leveraging rigorous research capabilities and efficient execution, HTX provides users with a diverse selection of high-quality digital assets. USD1, with its strong issuing team background, clear asset collateralization mechanisms, stringent audit processes, transparent regulatory pathway, and ambitious vision for financial freedom, aligns with HTX’s established criteria for selecting premium assets. By being the first to list USD1, HTX offers its users enhanced investment options while simultaneously promoting the widespread adoption of blockchain technology within the global financial framework.

From WLFI’s perspective, choosing HTX as the primary listing platform for USD1 was a strategic decision based on the exchange’s comprehensive global market competitiveness. HTX consistently leads the industry in user base, trading volume, ecosystem development, and technological security.

Special Promotion for USD1 Launch on HTX

To commemorate the initial listing of USD1, HTX is offering a limited-time zero-fee trading promotion. From May 6, 2025, at 11:00 to December 31, 2025, at 23:59 (GMT+8), the USD1/USDT spot trading pair will be available with zero transaction fees. HTX’s rapid response and seamless user experience provide global users with an exceptional opportunity to participate early in the USD1 ecosystem.

Powerful Alliance Forges a New Chapter in Decentralized Finance

The launch of USD1 signifies a pivotal advancement in the stablecoin landscape. As the premier global listing platform for USD1, HTX, with its robust ecosystem resources and global influence, provides boundless possibilities for the rapid adoption and expanded use cases of USD1.

As Justin articulated at the TOKEN 2049 summit, “We stand at a historical juncture where blockchain technology will redefine the boundaries of financial freedom.” Moving forward, HTX will continue to uphold its principles of openness and innovation, collaborating with leading global projects to provide users with safer, more convenient, and efficient digital asset services, collectively shaping a remarkable future for decentralized finance.

About HTX

Founded in 2013, HTX has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,” HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.

To learn more about HTX, please visit HTX Square or https://www.htx.com/, and follow HTX on X, Telegram, and Discord.

Noodoe Unveils AI-Driven EV Charging, Driving Toward Autonomous Transportation

RICHARDSON, Texas, May 6, 2025 /PRNewswire/ — Noodoe, a global innovator in EV charging and energy management solutions, has launched its groundbreaking AI-powered charging management system, paving the way for the next generation of transportation. Featured in a recent Amazon Web Services (AWS) case study, Noodoe’s AI Advisor uses generative AI technology to optimize EV charging station pricing strategies, significantly enhancing revenues and station utilization, and setting the foundation for future autonomous vehicle integration.

Noodoe Boosts EV Charging Station Revenues by 10–25% with Generative AI Advisor
Noodoe Boosts EV Charging Station Revenues by 10–25% with Generative AI Advisor

Noodoe’s innovative AI-powered EV charging platform analyzes charging data in real time, providing station operators with optimized pricing recommendations tailored to individual charging stations. Within months of deployment, the solution has driven revenue increases of 10 to 25 percent per charging station.

“We are delivering smarter, AI-driven solutions today while laying the groundwork for future transportation infrastructure,” said Jennifer Chang, CEO of Noodoe. “AI Advisor is just the beginning. We’re actively building the next generation EV charging ecosystem essential for autonomous vehicle deployment.”

The solution, which integrates seamlessly into Noodoe’s time-proven operating system, underscores the company’s commitment to pioneering advanced, intelligent energy management technology. By employing advanced autonomous management and generative AI, Noodoe has achieved industry-leading operational reliability, maintaining 98 percent network uptime, strides beyond the industry average.

“We are excited about the immediate impacts our AI-powered system is delivering,” noted Roman Kleinerman, VP of Products at Noodoe. “This development has accelerated our innovation cycle, enabling us to deliver cutting-edge, data-driven insights to our customers and prepare for the broader transition to autonomous transportation.”

The full AWS case study detailing Noodoe’s AI-driven success story can be accessed here: https://aws.amazon.com/solutions/case-studies/noodoe/

About Noodoe: Noodoe is at the forefront of the EV revolution. Dedicated to facilitating the global transition towards sustainable, autonomous transportation through technical leadership and AI-powered software solutions, Noodoe creates the custom-built EV Operating System (EV OS) that empowers businesses worldwide to seamlessly enter or expand in local EV charging markets. Noodoe EV OS offers comprehensive solutions to many of the industry’s stickiest problems, automating and streamlining EV charging operations with cutting-edge reliability and the leading user experience. Committed to continuous innovation, Noodoe sets the bar for intelligent management systems in the EV charging industry. www.noodoe.com

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes

Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S.

MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ — Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment by Eshelman Ventures, LLC and appointment of Dr. Eshelman as a strategic advisor for Paradigm. SD-101 (Zorblisa™) is being developed as a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB) patients. Funds will be used to complete all activities to support an NDA submission in the later part of 2025.

“We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa™) and to move a path forward towards registration of this therapy for patients with all EB subtypes,” said Robert Ryan., Ph.D., Chief Executive Officer of Paradigm Therapeutics. “There is a tremendous need for novel whole skin surface treatment options for treating the debilitating skin effects across all patients with Epidermolysis Bullosa. The Paradigm Therapeutics team will be working passionately to provide patients with a new therapeutic alternative in this disease with limited whole-body treatment options. Paradigm’s goal is to provide this therapy to patients on a global basis and is working in parallel with potential partners to work towards this goal as quickly as possible.”

Dr. Ryan added, “Epidermolysis Bullosa is a devastating disease. We believe the clinical data show beneficial effects of the use of SD-101 across the range of EB patients, and strongly support progression towards registration. Results from the completed Phase II and Phase III trials indicate that SD-101 demonstrated a broad benefit with whole body treatment of the lesions and wounds on the entire skin surface in pediatric and adult patients across all EB patients, who have limited whole body treatment alternatives. Results also demonstrated that SD-101 has a favorable safety profile when used long term.”

“Eshelman Ventures is honored to invest in Paradigm Therapeutics and play a pivotal role in accelerating the development of SD-101 as a transformative treatment for Epidermolysis Bullosa,” said Dr. Eshelman, founder of Eshelman Ventures. “As an investor and strategic advisor, I am deeply committed to working closely with this exceptional team as we work tirelessly to bring this innovative therapy to patients in need. The urgency of addressing the challenges faced by EB patients is what drives us; our goal is to provide an improved quality of life in this area of unmet need. Together, we will strive to revolutionize treatment options and make a meaningful impact on the lives of those affected by this debilitating disease.”

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa is a rare, devastating genetic disorder causing very fragile skin that leads to severe skin blistering and open wounds often beginning at birth. There are no approved therapies that were developed to treat the entire skin surface of patients across all subtypes of EB patients, including wounds and lesional skin, which affects children and adults throughout their lifetimes. EB is a chronic disease, potentially disfiguring, and in some cases fatal. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma.

About SD-101 (Zorblisa™)

SD-101 (Zorblisa™) is a topical cream that has demonstrated potential to provide improvement in treating the severe skin disruptions seen in patients across all EB subtypes. Phase II and Phase III studies were conducted in children and adults with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. A total of 217 EB patients were included in these studies. SD-101 was applied topically over the entire body daily in adults and children as young as 21 days old for a period of three months. The primary outcome measurement was assessment of target wound closure, in addition to secondary measurements including reduction in body surface area (BSA) coverage of blisters and wounds.

SD-101 (Zorblisa™) was the first EB treatment to receive the FDA’s Breakthrough Therapy designation. SD-101 (Zorblisa™) received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of EB. In addition to the Rare Pediatric Disease designation, SD-101 was granted Orphan Drug designation from the FDA and the European Commission (EC). Upon approval, Paradigm will be eligible to receive a Priority Review Voucher (PRV).  

About Paradigm Therapeutics, Inc.

Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm’s main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblisa™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 (Zorblisa™) is a topical cream that requires no special handling and can be stored at room temperature and has demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. 

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Paradigm disclaims any intent or obligation to update these forward-looking statements.

Company Contact

Dr. Robert Ryan

Chief Executive Officer

rryan@paradigmtherapeutics.com

(919)-274-0703

TTEC Expands India Operations with New Mohali Customer Experience Center, Adding 400 New Jobs

AUSTIN, Texas and MOHALI, India, May 6, 2025 /PRNewswire/ — TTEC Holdings, Inc. (NASDAQ: TTEC), a leading global customer experience (CX) technology and services innovator, today announced the expansion of its India operations with a new customer experience center in Mohali, also known as Sahibzada Ajit Singh Nagar (SAS Nagar).

This expansion will create 400 new jobs to support a major U.S.-based healthcare organization, with capacity to grow and serve additional clients as TTEC expands in the region.

President of TTEC Engage John Abou commented: “Today’s customer experience leaders are looking for smarter, more agile ways to deliver value—and digital first CX programs are the answer. By combining the unique knowledge of our front-line teams with the precision of AI-powered insights, our new Mohali Customer Experience Center will enable clients to elevate outcomes, streamline operations, and do so with speed, efficiency, and confidence.”

TTEC chose Mohali for its expansion due to the region’s scalable, English-proficient talent pool and strong cultural alignment with the company’s service-first mindset. Local values like seva (selfless service) and community cohesion naturally support TTEC’s human-centered approach to customer experience.

TTEC’s Mohali Customer Experience Center will initially operate from C-205, Phase 8B, Industrial Area, Sector 74, Mohali, Punjab 140308. The company anticipates moving in August to Quark City, an IT and tech hub located in Mohali.

New hires at TTEC’s state-of-the-art Mohali Customer Experience Center will leverage the company’s latest AI-enabled technology to deliver seamless, human-centric service experiences. This includes TTEC Perform, an AI-powered performance enablement platform that helps frontline teams continually improve; TTEC Let Me Know, a generative AI tool that speeds knowledge retrieval to improve the customer and employee experience; and TTEC Clarity, which improves communication through accent softening and voice-to-voice translation.

“We’re thrilled to continue our growth in India with this expansion into Mohali,” said TTEC Engage Senior Vice President of Asia Pacific Operations Arnab Ray. “This investment reflects both the incredible talent in the region and TTEC’s continued commitment to delivering exceptional experiences for our clients and their customers.”

This move builds upon TTEC’s significant growth in India, where the company has been operating for 24 years. In 2024, TTEC celebrated the one-year anniversaries of its Mumbai Customer Experience Center and Hyderabad Digital Innovation Studio, adding 800 positions to support these facilities. With approximately 3,500 employees across India, including sites in Ahmedabad and Chennai, TTEC continues to invest in the region’s talent and infrastructure.

Interested candidates can learn more about TTEC’s Mohali location here and can explore and apply to open positions here.

About TTEC
TTEC (pronounced T-TEC) Holdings, Inc. (NASDAQ: TTEC) is a leading global CX (customer experience) technology and services innovator for AI-enabled digital CX solutions. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the entire enterprise, touch every virtual interaction channel, and improve each step of the customer journey. Leveraging next-gen digital technology, the Company’s TTEC Digital business designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The Company’s TTEC Engage business delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back office, and fraud prevention services. Founded in 1982, the Company’s singular obsession with CX excellence has earned it leading client, customer, and employee satisfaction scores across the globe. The Company’s employees operate on six continents and bring technology and humanity together to deliver happy customers and differentiated business results. To learn more visit us at ttec.com.

Media Contact:
Meredith Matthews
meredith.matthews@ttec.com
+1 281-770-2566